Studien - Niere
   
 

     
AUO Nr.: AN 38/15  Niere   Details zur Studie         
Titel: Nivoswitch - A randomized phase II study with NIVOlumab or continuation of therapy as an early SWITCH approach in patients with advanced or metastatic renal cell carcinoma (RCC) and disease control after 3 months of treatment with a tyrosine kinase inhibitor
Studienleiter: Herr Dr. med. Viktor Grünwald - Med. Hochschule Hannover   30625 Hannover Carl-Neuberg-Straße 1 Tel:0511/532-40 77  Gruenwald.Viktor@mh-hannover.de

     
AUO Nr.: AN 41/16 Niere   Details zur Studie         
Titel: Sunniforecast - A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Renal Cell Carcinoma
Studienleiter: Herr Prof. Dr. Lothar Bergmann - Klinikum d. J.-W.-Goethe-Universität  60590 Frankfurt/Main Theodor-Stern-Kai 7 Tel:069/63 01-51 30  L.Bergmann@em.uni-frankfurt.de

     
AUO Nr.: AN 42/16 Niere   Details zur Studie         
Titel: IMmotion-010 - A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) AS ADJUVANT THERAPY IN PATIENTS WITH RENAL CELL CARCINOMA AT HIGH RISK OF DEVELOPING METASTASIS FOLLOWING NEPHRECTOMY
Studienleiter: kein Einverständnis zur Veröffentlichung der Daten. Bitte haben Sie Verständnis dafür!

     
AUO Nr.: AN 43/17 Niere   Details zur Studie         
Titel: NIS NORA - A NATIONAL, PROSPECTIVE, NON-INTERVENTIONAL STUDY (NIS) OF NIVOLUMAB (BMS-936558) IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA AFTER PRIOR THERAPY
Studienleiter: Herr Prof. Dr. med. Marc-Oliver Grimm - Friedrich-Schiller-Universität Jena  07740 Jena Lessingstr. 1 Tel:03641/93 51 91  marc-oliver.grimm@med.uni-jena.de

     
AUO Nr.: AN 44/17 Niere   Details zur Studie         
Titel: CheckMate-914 - A Phase 3 Randomized Study Compa-ring Nivolumab and Ipilimumab Combi-nation vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrec-tomy and Who Are at High Risk of Relapse
Studienleiter: Herr PD Dr. Florian Imkamp - Med. Hochschule Hannover   30625 Hannover Carl-Neuberg-Str. 1 Tel:0511/532-66 73  imkamp.florian@mh-hannover.de